VEGI (Vascular Endothelial Growth Inhibitor) Antibody from MYBIOSOURCE INC.
Search, find, compare suppliers for anti-VEGI (Vascular Endothelial Growth Inhibitor) antibody, protein, ELISA kits.
| Edit | |
|---|---|
| Antigenic Specificity | VEGI (Vascular Endothelial Growth Inhibitor) |
| Clone | [VEGI/1283] |
| Host Species | Mouse |
| Reactive Species | human. |
| Isotype | IgG1, kappa |
| Format | unconjugated |
| Size | 0.02 mg (With BSA & Azide at 0.2mg/ml), 0.1 mg (With BSA & Azide at 0.2mg/ml), 0.1 mg (Without BSA at 1mg/ml) |
| Concentration | n/a |
| Applications | Flow Cytometry (FC/FACS), Immunofluorescence (IF), Western Blot (WB), Immunohistochemistry (IHC) Formalin |
| Reviews / Ratings | If you have used this antibody, please help fellow researchers by submitting reviews to pAbmAbs and antYbuddY. |
| Description | Specificity: VEGI is an anti-angiogenic cytokine that belongs to tumor necrosis factor superfamily, member 15 (TNFSF15). This protein is abundantly expressed in endothelial cells, but is not expressed in either B or T cells. The expression of this protein is inducible by TNF and IL-1 alpha. This cytokine is a ligand for receptor TNFRSF25 and decoy receptor TNFRSF21/DR6. It can activate NF-kappaB and MAP kinases, and acts as an autocrine factor to induce apoptosis in endothelial cells. This cytokine is also found to inhibit endothelial cell proliferation, and thus may function as an angiogenesis inhibitor. Reduced expression of VEGI has been reported as a marker of poor prognosis in breast cancer. |
| Immunogen | Immunogen: Recombinant human full-length VEGI fragment Cellular Localization: Secreted and Cell Surface |
| Other Names | [TNF ligand-related molecule 1 (TL1A); Tumor necrosis factor (ligand) superfamily member 15 (TNFSF15); Vascular endothelial growth inhibitor 192a; Vascular endothelial growth inhibitor (VEGI); VEGI192A] |
| Gene, Accession # | [VEGI], Gene ID: 9966, NCBI: NP_001191273.1, UniProt: O95150 |
| Catalog # | MBS4380376 |
| Price | $190, $340, $340 |
| Order / More Info | VEGI (Vascular Endothelial Growth Inhibitor) Antibody from MYBIOSOURCE INC. |
| Product Specific References | Parr C, Gan CH, Watkins G, Jiang WG. Reduced vascular endothelial growth inhibitor (VEGI) expression is associated with poor prognosis in breast cancer patients. Angiogenesis. 2006; 9(2):73-81. Zhai, Y., et al. 1999. Inhibition of angiogenesis and breast cancer xenograft tumor growth by VEGI, a novel cytokine of the TNF superfamily. Int. J. Cancer 82: 131-136. 5. Zhai, Y., et al. 1999. VEGI, a novel cytokine of the tumor necrosis factor family, is an angiogenesis inhibitor that suppresses the growth of colon carcinomas in vivo. FASEB J. 13: 181-189. |
MYBIOSOURCE INC.
MYBIOSOURCE INC.
P.O. Box 153308
San Diego CA 92195-3308
P: 1.858.633.0165
P: 1.888.MBS.0165 (1.888.627.0165) (US & Canada)
F: 1.858.633.0166
sales@mybiosource.com
http://www.MyBioSource.com
Profile of MYBIOSOURCE INC.
Return to Antibodies